T. Stepanova

GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection

W. Haefeli, S. Ciesek, H. Wedemeyer, 2019, Journal of Hepatology.

48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection

W. Haefeli, S. Ciesek, H. Wedemeyer, 2020, Journal of Hepatology.

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.

T. Asselah, M. Imamura, M. Yuen, 2022, The New England journal of medicine.

A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.

A. Berger, S. Ciesek, P. Lampertico, 2023, The New England journal of medicine.

Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study

S. Zeuzem, P. Lampertico, H. Wedemeyer, 2022, Journal of Hepatology.

Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks

M. Buti, R. Gish, P. Lampertico, 2022, Journal of Hepatology.

Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results from a Phase 3 Randomized, Multicenter, Parallel Design Study

S. Zeuzem, P. Lampertico, H. Wedemeyer, 2023, 39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber.